Daniel Arnold
Internal Medicine · Boston, MANPI 1679764773
Payments from drug & device makers
Across 100 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$454
- Novo Nordisk$296
- GSK$249
- Pfizer$232
- Novartis$194
- Abbott$136
- plus $892 from 17 others
What the payments were for
- Food & beverage$2,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $454 |
| Novo Nordisk | 11 | $296 |
| GSK | 7 | $249 |
| Pfizer | 11 | $232 |
| Novartis | 9 | $194 |
| Abbott | 1 | $136 |
| AbbVie | 5 | $124 |
| Exact Sciences | 5 | $112 |
| Alnylam Pharmaceuticals Inc. | 5 | $110 |
| Phathom Pharmaceuticals, Inc. | 4 | $80 |
| Eisai Inc. | 3 | $79 |
| Boston Scientific | 2 | $67 |
| Lilly USA, LLC | 3 | $64 |
| Bayer | 3 | $46 |
| Verona Pharma, Inc. | 2 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Lucid Diagnostics Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Merck | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre 2$136
- Wegovy$125
- AREXVY$118
How this compares
$2,453 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 187 | $218,299 |
| OzempicSemaglutide | 142 | $207,596 |
| MounjaroTirzepatide | 74 | $101,388 |
| JardianceEmpagliflozin | 81 | $96,015 |
| XareltoRivaroxaban | 51 | $70,027 |
| FarxigaDapagliflozin Propanediol | 31 | $33,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $28,839 |
| JanuviaSitagliptin Phosphate | 19 | $28,419 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 23 | $24,456 |
| Tresiba Flextouch U-100Insulin Degludec | 41 | $22,038 |
| Rosuvastatin Calcium | 646 | $21,880 |
| TrulicityDulaglutide | 16 | $20,993 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $20,268 |
| MyrbetriqMirabegron | 22 | $19,631 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $17,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $296 | $222,695157 claims |
| PfizerEliquis | $232 | $218,299187 claims |
| Lilly USA, LLCMounjaro, Trulicity | $64 | $122,38090 claims |
| Johnson & JohnsonXarelto | $16 | $70,02751 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Lamictal | $249 | $60,94472 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $454 | $53,62552 claims |
| MerckJanuvia | $16 | $28,41919 claims |
| AbbVieCreon, Synthroid | $124 | $19,118109 claims |
| NovartisEntresto | $194 | $7,60111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Boston
- Noopur RajeBoston$19.9M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Elizabeth LeeBoston$9.8M
- Xiuning leBoston$7.9M
- Adrienne WaksBoston$7.3M
- Ibiayi Dagogo-JackBoston$5.8M
- Bilal SiddiquiBoston$5.4M
- David SchenkeinBoston$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.